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Strongyloides stercoralis is a soil-transmitted helminth 
widely diffused in tropical and subtropical regions of 
the world. Autochthonous cases have been also diag-
nosed sporadically in areas of temperate climate. We 
aimed at defining the epidemiology of strongyloidia-
sis in immigrants and Italians living in three northern 
Italian Regions. Screening for S. stercoralis infection 
was done with serology, confirmation tests were a 
second serological method or stool agar culture. A 
case–control approach was adopted and patients with 
a peripheral eosinophil count ≥ 500/mcL were classi-
fied as cases. Of 2,701 individuals enrolled here 1,351 
were cases and 1,350 controls; 86% were Italians, 48% 
women. Italians testing positive were in 8% (97/1,137) 
cases and 1% (13/1,178) controls (adjusted odds ratio 
(aOR) 8.2; 95% confidence interval (CI): 4.5–14.8), 
while positive immigrants were in 17% (36/214) cases 
and in 2% (3/172) controls (aOR 9.6; 95% CI: 2.9–32.4). 
Factors associated with a higher risk of infection for 
all study participants were eosinophilia (p < 0.001) and 
immigration (p = 0.001). Overall, strongyloidiasis was 
nine-times more frequent in individuals with eosino-
philia than in those with normal eosinophil count.
Introduction
Strongyloides stercoralis is a soil-transmitted helminth 
affecting millions of people worldwide [1,2]. Its trans-
mission occurs in areas where poor hygienic condi-
tions and humid, warm climate permit the free-living 
cycle of the parasite. The larvae present in the soil can 
penetrate human skin, therefore barefoot walking and 
agricultural activities pose people at risk of acquiring 
the infection. S. stercoralis produces larvae that can 
reinfect the host by a so called auto-infective cycle, a 
peculiarity shared only by Capillaria spp [3], so that an 
infected person remains infected life-long, if not prop-
erly treated [4]. This is the reason why strongyloidia-
sis can be diagnosed in people who have left endemic 
countries already several years before.
The few studies conducted in the United States (US) 
and in Europe to evaluate the prevalence of strongy-
loidiasis in immigrants and refugees from endemic 
countries, either through population or hospital-based 
studies, probably underestimated the real burden of 
the infection as long as microscopic stool examina-
tion was the only test used for screening [5]. In fact, 
the methods commonly employed for stool micros-
copy such as formalin-ether concentration, have a low 
sensitivity. Preferred faecal-based methods for the 
detection of S. stercoralis are Baermann funnel concen-
tration and agar plate culture (APC), but the method 
that has so far demonstrated the highest sensitivity is 
serology [6]. Studies conducted in the field, classically 
underestimate the burden of strongyloidiasis if there 
is no special focus on this infection i.e. through using 
an appropriate diagnostic method. This is why the ‘old’ 
estimates of prevalence from the late 1980s and 1990s 
[7,8] were recently questioned [1,2].
The transmission of strongyloidiasis occurs especially 
in tropical and subtropical areas. However, in some 
temperate countries, autochthonous transmission 
occurred in the past [9,10], or might be still ongoing 
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[11,12]. Therefore, cases of S. stercoralis infection can 
be diagnosed in people who have never moved from 
the Mediterranean coast.
Strongyloidiasis can be fatal in immunocompromised 
patients so prompt diagnosis and effective treatment 
are crucial for all those infected, in order to prevent 
later complications, such as disseminated strongyloi-
diasis [4]. Chronic infection is characterised by mild, 
unspecific symptoms such as pruritus, abdominal pain 
or discomfort, respiratory impairment which are not 
easily attributable to S. stercoralis and there is no full 
agreement among experts on considering eosinophilia 
as a predictor of the infection [13]. However, in non-
endemic countries a high eosinophil count might be a 
sufficient index of suspicion in travellers or in patients 
over 65 years with history of barefoot walking in a for-
merly endemic area [14,15].
The treatment of choice for strongyloidiasis is iver-
mectin that has demonstrated a higher efficacy than 
albendazole [16]. Although the drug is included in the 
World Health Organization (WHO) list of essential med-
icines [17], it is not accessible for the vast majority of 
infected people in the world [18,19]. In fact, this essen-
tial drug is still donated to endemic countries, but with 
the strict limitation of use for Wuchereria bancrofti and 
Onchocerca volvulus control programmes [20]. In Italy, 
ivermectin has never been registered for human use.
In a previous pilot study, we screened 132 Italian indi-
viduals born in 1940 or earlier, with eosinophilia and 
no significant travel history, presenting to the clinical 
laboratories of two health districts. The serology test, 
an in-house immunofluorescence antibody test (IFAT), 
was positive in 28% of cases, suggesting that strongy-
loidiasis can be a relevant cause of eosinophilia in this 
group of individuals [9].
In the present study, we extended the previous 
screening in order to estimate the prevalence of 
strongyloidiasis in six provinces of three Italian 
Regions. The population analysed included both adult 
Figure 1
Map of northern Italy showing where participating sites are situated, study of Strongyloides stercoralis epidemiology, 
northern Italy, February 2013–July 2014
The names of the study sites are in red.
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immigrants and Italians born before 1952, with or with-
out eosinophilia.
Methods
Study design and setting
We conducted a multicentre case–control study.
Participants were enrolled between 2 February 2013 
and 27 July 2014. The enrolling sites were the outpa-
tient blood sampling sectors of seven hospitals located 
in three Italian Regions: Veneto (Negrar, San Bonifacio, 
and Treviso sites), Lombardia (Brescia, Mantova sites), 
and Friuli Venezia Giulia (Trieste, Udine sites) (Figure 
1). The Centre for Tropical Diseases of Negrar (CTD) and 
the Health Prevention Department, Verona, were the 
coordinating centres.
On 1 January 2013, according to the Italian National 
Institute of Statistics [21], the total resident population 
in the six provinces of the three Regions involved in 
the study was 4,215,423 people (3,742,724 Italian and 
472,699 foreign residents). With regard to Italian resi-
dents, 1,074,367 (28.7%) were > 60 years (born before 
1952), which was the age cut off for inclusion of Italians 
in the present study. As for immigrants, 351,347 (74.3%) 
were > 17 years old, which was the age criterion for their 
inclusion in the present study.
Participants
Investigators proposed the screening to individuals 
meeting the inclusion criteria and consecutively pre-
senting as outpatients to perform a full blood count 
to one of the collaborating laboratories, during 20 
randomly-selected weeks. For the study purpose, we 
adopted the following definitions:
• Cases: individuals with peripheral eosinophil 
count ≥ 500/mcL;
• Controls: individuals with eosinophil count < 500/
mcL;
• Italians: individuals born and resident in Italy;
• Immigrants: individuals who were born in an endemic 
area and resided there for at least the first two years 
of life, and without Italian citizenship.
Each selected week, every centre had to recruit 10 
cases and 10 controls. Inclusion criteria were: Italians 
born before 1952 (as in CTD experience with hundreds 
of patients the infection was extremely rare in younger 
Italian individuals with no travel history), immigrants 
aged ≥ 18 years. Each participant gave informed writ-
ten consent. Individuals included in the study received 
a copy of the result of the test(s) performed and, in 
case of positive or uncertain result, a treatment with 
ivermectin (200 µg/kg, stat dose) was offered. A case 
report form (CRF) with essential clinical data was filled 
for those with positive test results.
Laboratory methods
Screening for S. stercoralis infection was performed 
with a commercial ELISA test, IVD Research, CA, USA 
ELISA (IVD ELISA) during 2013, then Bordier ELISA until 
the end of the study period, due to unavailability of 
the former test; positive samples were tested with an 
in-house IFAT [22]. Discordant samples were analysed 
with Bordier ELISA during 2013, until when IVD ELISA 
was used as the screening test. Subsequently, due to 
unavailability of the latter test, Bordier ELISA was used 
as the screening test, and a third testing for discord-
ant samples was no longer possible. The three tests 
have been described in detail elsewhere [23]. Patients 
testing positive in the screening tests were invited to 
supply a faecal sample for Koga agar plate culture for 
S. stercoralis [24] and/or for copro-parasitological test 
(formalin-ether concentration).
For the study purpose, patients were defined as ‘posi-
tive’ in case of two concordant positive serologic tests 
and/or a positive screening test AND a positive APC /
copro-parasitological test. Individuals with only one 
positive screening test and negative stool test were 
classified as ‘uncertain’ in case a third serologic test 
was unavailable.
Study size
There is scarce data on the prevalence of strongyloidia-
sis in Italy. Previous, smaller studies, found a preva-
lence between 10 and 15% in Italians with eosinophilia 
aged >60 and >68 years, respectively, and around 4% in 
controls of the same age group with normal eosinophil 
count [9,14]. On the basis of these surveys, the study 
size was calculated considering an odds ratio (OR) 
for suspected/confirmed strongyloidiasis in cases vs 
controls of 3, a case/control ratio of 1:1, a prevalence 
Figure 2
Flowchart for inclusion of participants in study of 





Excluded cases  (n=324)
256 Italians and 68 immigrants 
refused participation
Excluded controls  (n=192) 
No available information about 
ethnicity of those who refused 
participation
1,351 cases
1,137 Italians 1,178 Italians214 immigrants 172 immigrants
1,350 controls
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of strongyloidiasis in the control group of 3%, a con-
fidence level at 95%, a study power of 80% and a 
design effect of 1.5. Eventually, a total of 950 Italians 
were to be tested, 475 cases and controls, respectively. 
Therefore, we initially established to enroll at least 
500 individuals per group (1,000 Italian individuals in 
total).
The literature demonstrates a high variability in the 
prevalence of strongyloidiasis in immigrants, depend-
ing on their country of origin and on the screening 
method used [5]. Studies based on serology demon-
strated a prevalence between 10 and 36%, irrespective 
of the eosinophil count. To calculate the study size we 
assumed an OR (for strongyloidiasis in cases vs con-
trols) of 3 and a study power 80%. Based on these 
data, the minimum number of immigrants to be tested 
was 185 for each group, resulting in a total number of 
370. Therefore, we attempted to enroll 200 individuals 
per group, 400 immigrants in total.
Overall, the minimal sample size required was of 1,400 
individuals. As the sample size calculation was based 
on very weak estimates, particularly for Italian indi-
viduals for whom no formal, previous prevalence study 
was available, the proposed target sample was twice 
as large i.e. 2,800 individuals, 200 cases and 200 con-
trols to be recruited by each study site.
Statistical methods
Data at each centre were entered in a pre-structured 
Excel file and analysed using Stata 10 software (Stata 
Corp., Texas, US). For quantitative variables, data dis-
tribution was checked for normality by Shapiro-Francia 
test.
Since data were not normally distributed, they were 
analysed using the non-parametric Mann–Whitney test 
and the variations among groups were calculated as 
medians with interquartile ranges (IQR). Associations 
among categorical variables were analysed by 
Pearson’s chi-squared test or Fisher’s exact test as 
appropriate, and presented as observed frequencies 
and proportions. Trend analysis was performed by 
chi-squared test for linear trend. The OR of finding the 
outcome of interest (i.e. S. stercoralis infection) in rela-
tionship to the eosinophil count (defining cases and 
controls) and to other variables of interest (sex, age, 
recruitment site, geographical area of origin) were cal-
culated by logistic regression. For all tests, the level 
chosen to indicate statistical significance was p < 0.05 
(two-tailed).
Ethical issues
The Ethics Committee of the coordinating centres 
(Comitato Etico della Provincia di Verona) approved the 
study protocol on 17 January 2012. The study protocol 
was then submitted to the Ethics Committees of each 
of the study sites, and formally approved.
All study participants received an information sheet 
and a letter for their general practitioner, explaining 
aim and methods of the study; signed informed con-
sent form was required.
Results
Participants
A total of 3,217 individuals fulfilled the inclusion cri-
teria; 516 were not included in the study because they 
were unable to give informed consent or refused to 
participate. The total number of individuals included 
in the study and analysed was 2,701 (Figure 2). 
The study population comprised 1,392 men (52%) and 
1,309 (48%) women. Each participating centre recruited 
ca 400 individuals.
Among 2,315 Italians, the proportion of women was 41% 
(n=464) for the 1,137 cases and 53% (n=625) for the 
1,178 total controls. Median age was 73 years (range: 
61–99; IQR: 67–78) and 72 years (range: 61–94; IQR: 
67–77) for cases and controls, respectively. Median 
value of eosinophil count was 630/mcL (range: 500–
24,890; IQR: 550–790) and 150/mcL (range: 0–490; 
IQR: 100–220) for cases and controls, respectively.
Among 386 immigrants, women represented 48% 
(n=103) of the 214 cases, and the proportion was 
higher for the 172 controls, 68% (n=117). Median age 
was 38 years (range: 18–87; IQR: 30–48) and 40 years 
(range: 18–83; IQR: 29–53) for cases and controls, 
respectively. Median value of eosinophil count was 
655/mcL (range: 500–2,380; IQR: 570–830) and 145/
mcL (range: 0–460; IQR: 70–240) for the cases and the 
controls, respectively.
Immigrants originated from Europe, especially east-
ern Europe and the Balkans (26%, n=101), Asia (22%, 
n=83), Sub-Saharan Africa (21%, n=82), North Africa 
and Middle East (18%, n=68), and Latin America (13%, 
n=52).
Figure 3
Percentage of positivity for Strongyloides stercoralis in 
relation to eosinophil count in Italians and in immigrants, 
study of S. stercoralis epidemiology, northern Italy, 


































Prevalence in cases and in controls
Overall, of 2,701 participating individuals, 149 (5%) 
were classified as positive (110 Italians and 39 immi-
grants) and 32 (1%) as uncertain (29 Italians and 3 
immigrants).
Among Italians with eosinophilia (cases) 8% (97/1,137) 
were positive vs 1% (13/1,178) without eosinophilia. 
Considering a total population of the same age group 
of 1,074,367 in the six provinces, and an average of 4% 
of subjects of the same age with eosinophilia (data not 
shown), we obtain a rough estimate of 4,000 Italians 
over 60 years of age with S. stercoralis infection.
Among immigrants, positive cases were 17% (36/214) 
vs 2% positive controls (3/172), respectively. The pro-
portion of positives was significantly higher among 
cases, both for Italians (p < 0.001) and immigrants 
(p < 0.001). Moreover, the higher the eosinophil count, 
the higher was the proportion of infected individuals, 
in both groups. Among Italians, the proportion of posi-
tive individuals ranged from 4% (31/780) for those with 
eosinophil counts between 500 and 749/mcL, to 39% 
(21/54) for those with eosinophil counts ≥ 1,500/mcL 
(p < 0.001) (Figure 3).
Among immigrants, this proportion ranged from 
11% (15/138) for those with eosinophils between 500 
and 749/mcL, to 60% (6/10) for those with eosino-
phils ≥ 1,500/mcL (p < 0.001) (Figure 3), albeit numbers 
were small in the latter group. Moreover, among the 
Italian cases, the proportion of positive individuals 
showed an upward trend with increasing age (p < 0.001) 
and varied depending on the study site (p = 0.01), with 
a peak in individuals born before 1936 (46/380; 12%) 
and in those recruited in the sites located in agricul-
tural regions of the Po valley (e.g. San Bonifacio site: 
19/146; 13%).
Immigrant cases had the following distribution, accord-
ing to the region of origin of the patients: Latin America 
(6/31), Sub-Saharan Africa (14/48 ), Asia (11/55), Europe 
(2/44), and North Africa (3/36).
Some of the individuals who were positive in the 
screening test refused to provide a stool sample, 
therefore the results of stool tests were available only 
for 70% (104/149) of patients with positive serology 
of which 28% (n=29/104) had a positive stool result. 
Ninety-nine of 149 positive patients (66%), plus seven 
individuals with uncertain result, received ivermectin 
treatment, offered free of charge to all eligible patients. 
Information about possible risk factors for complicated 
strongyloidiasis was available for 83% (124/149) posi-
tive individuals: 16% (20/124) presented a current or 
past condition considered to constitute a risk for the 
development of severe strongyloidiasis. In the latter 
group, most (17/20) were treated, while two individuals 
refused and one died of metastatic breast cancer soon 
after being tested.
Analysis on the subgroup of 54 of 149 positive indi-
viduals who answered the questionnaire showed that 
the majority had signs and symptoms compatible with 
strongyloidiasis (Table 1) and had been exposed to a 
risk factor for infection (farm work 32/54; walking bare-
foot in earlier years 37/54 ). Only two of 43 respond-
ing Italians reported a stay longer than one month in 
endemic countries, where they might have had contact 
with contaminated soil. The remaining Italians did not 
present a relevant travel history, so we assume that 
the infection was probably acquired in Italy.
By logistic regression, eosinophilia (p < 0.001) and 
immigration (p = 0.001) were independent risk factors 
for infection for all participants. After adjusting for 
birth cohort, sex and site of recruitment for Italians, 
or age, sex and geographical area of origin for immi-
grants, presence of eosinophilia ≥ 500/mcL was sig-
nificantly associated with infection both in Italians 
(adjusted OR: 8.18; 95% CI: 4.53–14.76; p < 0.001) 
and in immigrants (aOR: 9.62; 95% CI: 2.85–32.41; 
p < 0.001). Among Italians, year of birth and site of 
recruitment maintained a significant association with 
infection also at the multivariate analysis (Table 2); the 
same occurred among immigrants with regard to area 
of origin (Table 3).
Discussion
The high number of screened individuals, especially 
Italians, in our study, permitted to obtain a valuable 
estimate of the prevalence of strongyloidiasis in the 
Table 1
Signs and symptoms compatible with strongyloidiasis in individuals testing positive who answered a questionnaire, study of 
Strongyloides stercoralis epidemiology, northern Italy, February 2013–July 2014 (n = 54)
Signs and symptoms Number of Italians (%) n=43
Number of immigrants (%) 
n=11
Total number (%) 
n=54
Pruritus 23 (53.5) 4 (36.4) 27 (50)
Skin rash 13 (30.2) 2 (18.2) 15 (27.8)
Respiratory symptoms 16 (37.2) 3 (27.3) 19 (35.2)
Abdominal pain 9 (20.9) 1 (9.1) 10 (18.5)
Diarrhoea 1 (2.3) 2 (18.2) 3 (5.6)
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studied regions in the north of Italy: 8 and 17%, respec-
tively, in Italians and immigrants with eosinophilia, 1 
and 2% in those with a normal eosinophil count, irre-
spective of signs/symptoms of the infection. This find-
ing is relevant for autochthonous Italians, for whom 
prevalence data were previously limited and patchy, 
and this study demonstrated a considerable proportion 
of infected individuals. In addition, 2% of Italian con-
trols without eosinophilia with positive/uncertain test 
result is worth of note. The findings indicate that the 
infection is not an extinguished problem among elderly 
Italians living in the study areas.
The geographical pattern of infection prevalence is 
consistent with a higher transmission in agricultural 
areas of Po valley during the first decades of the past 
century, with a downward trend over time likely due 
to improvement of hygiene and sanitary conditions. 
Parts of the country, in the centre and in the south, 
presented in the past characteristics that make a loca-
tion suitable for the free-living cycle of S. stercoralis. It 
is thus probable that a similar epidemiological picture 
might be prevalent in a large part, if not in the whole, of 
Italy. This could also be true for other countries in the 
Mediterranean basin, where sporadic autochthonous 
strongyloidiasis cases have been diagnosed [10,12].
Among immigrants, the proportion of positive individu-
als was high among cases with eosinophil counts ≥ 500/
mcL, particularly if individuals originated from Sub-
Saharan Africa, Asia, and Latin America.
Prevalence data are fundamental to implement screen-
ing and prevention programmes. We believe our results 
support the establishment of risk categories for screen-
ing individuals at risk of developing strongyloidiasis, 
such as elderly Italians (and, probably, Europeans from 
other Mediterranean countries) and immigrants with 
eosinophilia. In the latter group, it might be even cost-
effective to treat all patients without testing [4]. This 
should, however, be demonstrated by a well-designed 
study, also considering that a pre-treatment diagnostic 
evaluation (obligatorily including serology) is crucial to 
monitor cure at follow-up [25].
One in three of the infected individuals refused the 
treatment that was offered free of charge after a thor-
ough explanation of the risk associated with untreated, 
chronic infection. Even general practitioners were not 
always keen to collaborate. Our experience suggests 
that strongyloidiasis is not always perceived as a rel-
evant health problem, not only by the general popula-
tion, but also by the medical community. To overcome 
this problem, it would be advisable to create national 
guidelines for the screening and management of eosin-
ophilia that should consider strongyloidiasis among 
the differential diagnoses. Moreover, considering that 
strongyloidiasis can be fatal in immunocompromised 
individuals, S. stercoralis should be included in guide-
lines/protocols for screening of candidate patients for 
immune-suppressant therapies, such as the oncologi-
cal and rheumatological ones.
Limitations
We faced some difficulties in finding eligible immi-
grants for inclusion in the study, therefore the number 
of immigrants enrolled was slightly lower than planned. 
This was the reason, in addition to that provided in the 
Methods part, to recruit a higher number of Italians 
than the initially calculated sample size, as we did not 
deem it appropriate, to stop the recruitment in this 
group and continue only with immigrants. We did not 
include in the analysis the countries of origin as num-
bers for such analysis were too small and instead we 
analysed the continents/macro-areas. We still believe 
the results are useful, considering the paucity of simi-
lar data in the literature. Although the included indi-
viduals were not randomly extracted from the general 
population, the enrolment of out-patients, coming to 
the hospital laboratory to perform a very simple and 
common test (full blood count), results in a sample that 
can be comparable to the general population in that 
age range, in particular for the larger Italian group. The 
controls were unmatched, but consecutively recruited 
on a randomly selected day on a 1:1 basis, within the 
same main group (Italian or immigrant) and age range.
Finally, the accuracy of serology is high, but false-pos-
itive and false-negative results can occur [23]. The use 
of a second, confirmatory serological test in addition 
to the faecal-based tests, when available, was aimed 
to increase the specificity of the results. Sensitivity 
can be lower in immunocompromised individuals [26], 
however, we believe that this may have had a minimal 
influence on the overall results, given the high number 
Table 2
Logistic regression analysis of factors associated with 
Italians testing positive for Strongyloides stercoralis, study 
of S. stercoralis epidemiology, northern Italy, February 
2013–July 2014 (n = 2,315 of which 1,137 cases and 1,178 
controls)
Factors OR 95% CI P value
Eosinophil count ≥ 500/mcL 8.18 4.53–14.76 < 0.001
Sex (male vs female) 0.93 0.63–1.39 0.730
Year of birth 
    1947–1951 1.00 Reference NA.
    1937–1946 2.56 1.24–5.28 0.011
    1936 or before 3.95 1.90–8.20 < 0.001
Recruitment site 
    Trieste 1.00 Reference NA
    Udine 1.34 0.54–3.32 0.52
    Negrar 1.67 0.69–4.00 0.25
    Mantova 2.33 1.00–5.41 0.050
    Brescia 2.47 1.07–5.70 0.033
    Treviso 2.97 1.33–6.64 0.008
    San Bonifacio 3.43 1.54–7.68 0.003
CI: confidence interval; NA: not applicable; OR: odds ratio.
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of individuals screened [19]. The screening test had 
to be changed, however Bordier ELISA and IVD dem-
onstrated similar accuracy in our previous study [23]. 
Therefore, we believe that the number of patients posi-
tive at screening might not have been substantially dif-
ferent with IVD ELISA. On the other hand, this change 
entailed the lack of a third serology test, therefore 
patients with discordant results had to be classified as 
uncertain. PCR was not available at our Centre before 
2014, hence we could not use this method, that showed 
good accuracy compared with APC and Baermann tech-
nique [27,28]. PCR is less cumbersome than the tradi-
tional faecal-based methods and the samples can be 
stored (either frozen or with ethanol), therefore it could 
have been a useful tool considering the high number of 
individuals screened.
Conclusions
The improvement of hygienic conditions and sanita-
tion, and the availability of deworming drugs are likely 
to successfully control most helminth infections in 
endemic areas in the forthcoming years. However, the 
lack of mass drug administration programmes specifi-
cally targeting S. stercoralis (using ivermectin) might 
lead to long-term persistence of this infection in some 
individuals. It is also important to note that, due to the 
peculiarity of the auto-infective cycle of S. stercora-
lis, this parasite may remain once the other helminth 
infections have disappeared. This has been observed 
in Italy. Physicians should be aware of the categories 
of patients that would require screening for S. stercora-
lis infection.
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